Artificial Pancreas Market Industry Bone Degeneration Therapeutics Market - Global Industry Insights, Trends and Opportunity Analysis, 2016–2024 [DATE] [COMPANY NAME] [Company address] Report Description Bone Degeneration Therapeutics Market Overview Bone Degeneration is characterized by deterioration of articular cartilage covering the joints. Cartilage aids free movement of the joint without any resistance. Reduction in flexibility of the joint due to deterioration of cartilage leads to inflammation, compressed nerves, and pain. Aging is one of the natural causes of bone degeneration, which is also fueled by several conditions such as injuries, congenital disorders, diabetes, and obesity. Symptoms of degenerative bone disorders includes joint stiffness, radiating pain that initiates in the back and spreads through the extremities and causes joint inflammation. Osteoporosis – characterized by existence of porous bones may lead to fractures There are two levels of bone loss that can result in an increased risk of fractures. Osteoporosis and osteopenia constitute two levels of bone loss. Osteopenia is considered as loss of bone material density, which indicates thinning of bones. Osteoporosis is a bone degeneration condition characterized by the existence of porous bones and it develops with time as bones slowly lose minerals, structure, and density, resulting in weaker bones. Eventually, osteoporosis leads to bent posture, cracked bones, and loss of height. Ask for Free TOC @ https://www.coherentmarketinsights.com/ongoing-insight/toc/94 Excessive bone degeneration results in fragile bones that are highly susceptible to fracture. There are several tests such as bone densitometers and dual energy x-ray absorptiometry scans performed to determine the density of bones. Stimulation of soft tissues and cartilage repair with prolotherapy represents some of the ways of alleviating pain resulting from degenerative bone disorders. Increasing diabetes incidence and rising obesity driving growth of the bone degeneration therapeutics market Factors such as increased physical inactivity, rising obesity, and increasing rate of diabetes are fueling growth of the bone degeneration therapeutics market. According to World Health Organization (WHO) around 422 million people worldwide suffered from diabetes in 2014. Increasing number of diabetic patients is fueling growth of the bone degeneration therapeutics market. Various products in research pipeline to augment the bone degeneration therapeutics market growth Bone degeneration therapeutics market can be segmented by treatment and application. By treatment, the bone degeneration therapeutics market can be segmented into device, drug, and surgery. Braces or sleeves are used to relieve pain caused due to bone degeneration. These provide pain relief to orthopedic patients. By drug, the bone degeneration therapeutics market is segmented into cortisone or steroids, hyaluronic acid and platelet-rich plasma. Platelet-rich plasma is effective in alleviating pain resulting from arthritis of the knee. Some products such as PREOB and ALLOB (both from Bone Therapeutics SA) are in research pipeline. PREOB received orphan drug designation for osteonecrosis in March 2008 from the U.S. FDA. On the basis of surgery, the bone degeneration therapeutics market is classified as arthroscopy, high tibial osteotomy, and knee replacement. By application, the bone degeneration therapeutics market can be segmented as osteoporosis, osteopenia, and spinal fusion. Denosumab injection (Prolia) is used to treat osteoporosis in men, post-menopausal women, people with increased risk for fractures, and those who cannot take or do not respond to other medications for osteoporosis. It is also used to treat bone loss in men suffering from prostate cancer and women with breast cancer. View the full Report @ https://www.coherentmarketinsights.com/ongoing-insight/bonedegeneration-therapeutics-market-94 Increasing sports injuries and growing aging population drives growth of the bone degeneration therapeutics market in North America The market for bone degeneration has significant potential in North America due to high incidence of sport injuries, availability of advanced technology, large aging population, robust medical infrastructure, and favorable government reimbursement policy. According to 2016 estimates of Osteoporosis Canada, over 80% of all fractures reported in people over 50 years of age are caused by osteoporosis and at least one in three women and one in five men suffer from an osteoporotic fracture during their lifetime. Asia Pacific is projected to be a high growth market for bone degeneration in the near future due to increasing consumer health awareness and development of good diagnostic and treatment facilities in the region. Bone degeneration market: Key players Amgen, Inc., Fate Therapeutics, Inc., Bone Therapeutics SA, Juventus Therapeutics, Inc., Kaken Pharmaceutical Co., Ltd., Regenexx, and Se-cure Pharmaceuticals, Ltd. are some of the companies involved in development of bone degeneration therapeutic products. Regenexx stem cell and plateletrich plasma procedures are advanced regenerative injection treatment used to treat knee pai n due to arthritis, ligament injuries, and other degenerative conditions. About Us COMPANY OVERVIEW Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to help businesses around the globe deliver practical and lasting results through various recommendations about operational improvements, technologies, emerging market trends and new working methods. We offer both customized and syndicated market research reports that help our clients create visionary growth plans to provide traction to their business. We meticulously study emerging trends across various industries at both the global and regional levels to identify new opportunities for our clientele. Our global team of over 100 research analysts and freelance consultants provide market intelligence from the very molecular country level and also provide a global perspective of the market. Our team is of the most vital cog in our robust machinery that gives us the ability to deliver independent insight relying on our cognitive defusion training module.This allows for an objective and unbiased assessment of the market. We pride ourselves in my constantly striving to update our extremely in-depth understanding of the market by closely monitoring and analyzing markets, trends, and emerging best practices, across allfathomable industries under the sun. This enables us to equip our valued clientele with key decisive inputs to capitalize on lucrative growth opportunities in the market and to follow firmly position themselves on a high growth path in the future. Contact Us CORPORATE OFFICE: Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel No: (+1)206-701-6702 Email: sales@coherentmarketinsights.com Website: https://www.coherentmarketinsights.com/ Visit Blog: http://healthcaremarketconsulting.blogspot.in/

Various products in research pipeline to augment the bone degeneration therapeutics market growth Bone degeneration therapeutics market can be segmented by treatment and application. By treatment, the bone degeneration therapeutics market can be segmented into device, drug, and surgery. Braces or sleeves are used to relieve pain caused due to bone degeneration. These provide pain relief to orthopedic patients. By drug, the bone degeneration therapeutics market is segmented into cortisone or steroids, hyaluronic acid and platelet-rich plasma. Platelet-rich plasma is effective in alleviating pain resulting from arthritis of the knee. Some products such as PREOB and ALLOB (both from Bone Therapeutics SA) are in research pipeline. PREOB received orphan drug designation for osteonecrosis in March 2008 from the U.S. FDA. On the basis of surgery, the bone degeneration therapeutics market is classified as arthroscopy, high tibial osteotomy, and knee replacement. By application, the bone degeneration therapeutics market can be segmented as osteoporosis, osteopenia, and spinal fusion. Denosumab injection (Prolia) is used to treat osteoporosis in men, post-menopausal women, people with increased risk for fractures, and those who cannot take or do not respond to other medications for osteoporosis. It is also used to treat bone loss in men suffering from prostate cancer and women with breast cancer.